NASDAQ:FATE

Fate Therapeutics (FATE) Price Target & Analyst Ratings

$5.52

+0.36 (+6.98%)

(As of 06/6/2023 ET)

Compare

Today's Range: $5.06
▼
$5.56
50-Day Range: $4.89
▼
$6.59
52-Week Range: $4.02
▼
$37.13

Volume: 1.95 million shs
Average Volume: 3.20 million shs
Market Capitalization: $543.06 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $15.50

Fate Therapeutics Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Hold
Based on 21 Analyst Ratings

Consensus Analyst Price Target

$15.50
180.80% Upside

High Prediction	$65.00
Average Prediction	$15.50
Low Prediction	$5.00

Type	Current 6/7/22 to 6/7/23	1 Month Ago 5/8/22 to 5/8/23	3 Months Ago 3/9/22 to 3/9/23	1 Year Ago 6/7/21 to 6/7/22
Consensus Rating	Hold	Hold	Hold	Moderate Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	5 Buy rating(s)	5 Buy rating(s)	6 Buy rating(s)	8 Buy rating(s)
Hold	14 Hold rating(s)	15 Hold rating(s)	14 Hold rating(s)	3 Hold rating(s)
Sell	2 Sell rating(s)	2 Sell rating(s)	2 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$15.50	$16.24	$24.69	$80.36
Predicted Upside	180.80% Upside	41.72% Upside	80.35% Upside	65.01% Upside

Get Fate Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for FATE and its competitors with MarketBeat's FREE daily newsletter.

FATE Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

FATE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Fate Therapeutics Stock vs. The Competition

Type	Fate Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.14	2.66	2.49
Consensus Rating	Hold	Buy	Hold
Predicted Upside	180.80% Upside	1,247.88% Upside	221.88% Upside
News Sentiment Rating	Neutral News	Positive News	Positive News

Historical Target Prices and Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
5/4/2023	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$5.30 ➝ $5.00	-20.38%
5/4/2023	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	L. Watsek Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target		$8.00 ➝ $5.00	-20.89%
3/27/2023	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Equal Weight	$6.00	+8.89%
3/2/2023	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	$9.00 ➝ $10.00	+64.20%
3/1/2023	EF Hutton Acquisition Co. I Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy	$10.00	+58.23%
3/1/2023	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$12.00 ➝ $7.00	+14.38%

1/24/2023	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	R. Burns Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$115.00 ➝ $7.00	+26.13%
1/6/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight	$35.00 ➝ $8.00	+94.17%
1/6/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform
1/6/2023	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Hold	$46.00 ➝ $7.00	-36.36%
1/6/2023	SVB Leerink Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform	$62.00 ➝ $10.00	-9.09%
1/6/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Underperform
1/6/2023	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Nierengarten Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$42.00 ➝ $7.00	-36.36%
1/6/2023	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform	$20.00 ➝ $7.00	-36.36%
1/3/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral
12/22/2022	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform
12/15/2022	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Sell	$10.00	-34.94%
10/10/2022	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$42.00	+95.62%
7/28/2022	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Hold

(Data available from 6/6/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

FATE Price Target - Frequently Asked Questions

What is Fate Therapeutics's consensus rating and price target?: According to the issued ratings of 21 analysts in the last year, the consensus rating for Fate Therapeutics stock is Hold based on the current 2 sell ratings, 14 hold ratings and 5 buy ratings for FATE. The average twelve-month price prediction for Fate Therapeutics is $15.50 with a high price target of $65.00 and a low price target of $5.00. Learn more on FATE's analyst rating history.
Do Wall Street analysts like Fate Therapeutics more than its competitors?: Analysts like Fate Therapeutics less than other Medical companies. The consensus rating for Fate Therapeutics is Hold while the average consensus rating for medical companies is Buy. Learn more on how FATE compares to other companies.
Does Fate Therapeutics's stock price have much upside?: According to analysts, Fate Therapeutics's stock has a predicted upside of 45.74% based on their 12-month price targets.

What analysts cover Fate Therapeutics?: Fate Therapeutics has been rated by Cantor Fitzgerald, Stifel Nicolaus, and Wells Fargo & Company in the past 90 days.

Stock Ratings Reports and Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

This page (NASDAQ:FATE) was last updated on 6/7/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial